长江生命科技(00775.HK)中期纯利跌48.94%至8744.1万港元
格隆汇8月4日丨长江生命科技(00775.HK)公布,截至2020年6月30日止6个月,集团实现收入23.80亿港元,同比下降8.36%;公司股东权益应占溢利8744.1万港元,同比下降48.94%;每股基本溢利0.91港仙;不派中期股息。
2019新型冠状病毒持续肆虐,对全球商业活动造成广泛而深远的打击。长江生命科技保健业务据点所在的美国、加拿大及澳洲等国家,一度采取严格的封锁措施,包括禁止离家外出,以及关闭办公地点及零售商店。
这些措施严重影响公司的保健业务运作,技术人员及工人不能出勤,生产近乎停顿,产量大幅下降,导致保健产品业务的财务贡献于2020年上半年录得显著跌幅。
值得一提的是,疫症蔓延时,长江生命科技与有连系的医药公司及科研机构探讨方案以助遏止疫患扩散,期间签订协议,分销由新加坡研发的逆转录聚合酶链式反应(RT-PCR)检测试剂盒及以血清学为基础的快速检测试剂盒。公司继续朝此方向,与全球有连系的机构寻求可舒缓疫情的其他方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.